Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulant therapy.

Lori-Ann Linkins1, Jeffrey I Weitz

  • 1McMaster University and Henderson Research Center, Hamilton, Ontario, Canada L8V 1C3. llinkins@thrombosis.hhscr.org

Annual Review of Medicine
|January 22, 2005
PubMed
Summary

New anticoagulants offer improved options for preventing and treating blood clots, addressing limitations of older drugs like heparin and vitamin K antagonists for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Poly(sulfobetaine-<i>co</i>-oligoethylene Glycol Methyl Ether Methacrylate) Copolymers with Improved Anti-Fouling and Anti-Coagulant Properties.

Biomacromolecules·2026
Same author

A novel biosensor for measuring plasmin activity.

Research and practice in thrombosis and haemostasis·2026
Same author

From Rapid Reviews to Rapid Living Evidence Synthesis: Lessons From COVID-19 Vaccine Effectiveness Reviews for Canadian Public Health Decision-Making.

Campbell systematic reviews·2026
Same author

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Blood·2026
Same author

Long-Term Hydrophilic, Anti-Clotting, and Anti-Fibrotic Dynamic Covalent Silicone-Based Biomaterials.

Advanced healthcare materials·2026

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Traditional anticoagulants like heparin and vitamin K antagonists have limitations.
  • Development of novel anticoagulants aims to improve safety and efficacy.
  • Thrombosis remains a significant clinical challenge.

Purpose of the Study:

  • To review novel anticoagulant drugs.
  • To identify molecular targets of new anticoagulants.
  • To discuss clinical trial results and future opportunities.

Main Methods:

  • Literature review of new anticoagulant development.
  • Analysis of clinical trial data for novel agents.
  • Synthesis of information on molecular targets and clinical applications.

Main Results:

  • New parenteral and oral anticoagulants have been developed.
  • These agents target specific molecular pathways in coagulation.
  • Clinical trials demonstrate varying efficacy and safety profiles.

Conclusions:

  • Novel anticoagulants offer promising alternatives to existing therapies.
  • Understanding molecular targets is key to optimizing anticoagulant use.
  • Further research and clinical experience will define the role of new anticoagulants.

Related Experiment Videos